Blue Bird vs Dorman Products
BLBD and DORM side by side, both in motor vehicles and motor vehicle equipment. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BLBD and DORM compare
Dorman Products is the larger company, worth 2.2 times as much as Blue Bird ($4.0B against $1.8B).
On earnings, Blue Bird is cheaper: it trades at 7.0× trailing earnings, against 20.0× for Dorman Products.
Blue Bird grew revenue faster over the last twelve months (13.5% versus 2.2% for Dorman Products).
Blue Bird keeps more of each dollar of sales as profit, with a net margin of 17.5% compared with 9.3% at Dorman Products.
Blue Bird scores higher on the StockData Score (20 against 13 for Dorman Products), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BLBD | DORM |
|---|---|---|
| Size and price | ||
| Market cap | $1.8B | $4.0B |
| Share price | $57.56 | $134.55 |
| Change, 1 year | 11.9% | 0.40% |
| Change, 5 years | 145% | 14.0% |
| Beta (5Y) | 1.09 | 0.68 |
| Employees | 2,012 | 300 |
| StockData Score | ||
| Total score | 20 (better) | 13 |
| Valuation score | 5 (better) | 2 |
| Growth score | 5 (better) | 1 |
| Performance score | 5 | 5 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 7.0× (better) | 20.0× |
| P/S | 1.1× (better) | 1.8× |
| P/B | 2.8× | 2.5× (better) |
| EV/EBITDA | 8.5× (better) | 12.3× |
| P/FCF | 11.9× (better) | 14.7× |
| PEG | – | 1.00 |
| FCF yield | 8.4% (better) | 6.8% |
| Fair value | $92.53 | $113.99 |
| Margin of safety | 37.8% (better) | −18.0% |
| Growth | ||
| Revenue growth (TTM) | 13.5% (better) | 2.2% |
| Revenue growth, 5Y average | 11.0% | 14.3% (better) |
| Net income growth (TTM) | 143% (better) | −18.2% |
| EPS growth (TTM) | 135% (better) | −16.3% |
| EPS growth, 5Y average | 53.9% (better) | 15.0% |
| Profitability | ||
| Gross margin | 20.6% | 41.1% (better) |
| Operating margin | 11.8% | 13.3% (better) |
| Net margin | 17.5% (better) | 9.3% |
| FCF margin | 9.5% | 12.4% (better) |
| Return on equity | 64.3% (better) | 13.3% |
| Return on invested capital | 43.1% (better) | 11.5% |
| Financial health | ||
| Debt / equity | 0.13 (better) | 0.28 |
| Net debt / EBITDA | −0.14 | 0.79 (better) |
| Interest coverage | 27.9× (better) | 10.8× |
| Current ratio | 1.64 | 3.65 (better) |
| Altman Z-score | 4.64 | 4.95 (better) |
| Piotroski F-score | 7 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.44% | – |
| Shareholder yield | 0.44% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 97.6% |
| Held by insiders | 10.2% | 8.2% |
| Insider net buying, 12 months | −$2.3M | −$1.7M (better) |
| Short interest, % of float | 15.5% | 5.7% |
Go deeper
- BLBD stock overview
- BLBD income statement
- BLBD valuation and score
- DORM stock overview
- DORM income statement
- DORM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.